Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Assessment of Lytic Therapy Effect in Patients With Intermediate-High Risk Pulmonary Embolism for Prevention of Chronic Thromboembolic Pulmonary Hypertension: A Randomized, Double-Blind Trial Publisher



Mansouri P1 ; Rashidi AM1 ; Mansouri MH1 ; Sadeghi M2 ; Zavar R3 ; Amirpour A2 ; Hashemi SM4 ; Taheri M3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Hypertension Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Health Science Reports Published:2024


Abstract

Background and Aims: This study aims to compare the effectiveness of thrombolytic therapy and anticoagulation in preventing chronic thromboembolic pulmonary hypertension (CTEPH). Method: A total of 60 patients with intermediate-high risk pulmonary embolism (PE) were randomly assigned to receive either thrombolytic therapy (n = 30) or anticoagulation (n = 30). Results: Echocardiographic assessments demonstrated no significant differences between the two treatment approaches in terms of right ventricular size (RVS) (on discharge in thrombolytic group: 31.17 ± 3.43 vs. anticoagulant group: 32.73 ± 5.27, p = 0.912), tricuspid annular plane systolic excursion (TAPSE) (on discharge in thrombolytic group: 17.66 ± 2.39 vs. anticoagulant group: 16.73 ± 2.93, p = 0.290), and systolic pulmonary artery pressure (SPAP) (on discharge in thrombolytic group: 32.93 ± 9.73 vs. anticoagulant group: 34.46 ± 9.30, p = 0.840). However, significant changes were observed in all assessed parameters within each treatment group (p < 0.001). The 6-month follow-up showed no significant difference between the two groups in terms of CTEPH incidence (p = 0.781) or functional class of the patients (p = 0.135). Conclusion: Based on the findings of this study, neither thrombolytic therapy nor anticoagulation demonstrated superiority over the other in reducing adverse outcomes associated with intermediate-high risk PE, including right ventricular size, SPAP, TAPSE, or CTEPH. © 2024 The Authors. Health Science Reports published by Wiley Periodicals LLC.
Related Docs
1. Catheter-Directed Thrombolysis Vs Anticoagulation in Patients With Acute Intermediate-High-Risk Pulmonary Embolism: The Canary Randomized Clinical Trial, JAMA Cardiology (2022)
2. Incidence and Predictors of Chronic Thromboembolic Pulmonary Hypertension Following First Episode of Acute Pulmonary Embolism, Advances in Respiratory Medicine (2020)
3. Efficacy and Safety of Different Dosage of Recombinant Tissue-Type Plasminogen Activator (Rt-Pa) in the Treatment of Acute Pulmonary Embolism: A Systematic Review and Meta-Analysis, Iranian Journal of Pharmaceutical Research (2021)
4. Venous Thromboembolism, Practical Cardiology: Principles and Approaches (2022)
Experts (# of related papers)
View all Related Experts
Ali Hosseinsabet (2)
Yaser Jenab (2)